Polaris Pharma (6550.TW)

Executive Summary

Polaris Pharma is a multinational biotechnology company based in San Diego with a subsidiary in Chengdu, China, founded in 2006. The company specializes in amino acid deprivation therapy for cancer, with its lead biologic candidate ADI-PEG 20 (pegargiminase) in late-stage clinical development for multiple solid and hematologic tumors. ADI-PEG 20 works by depleting arginine, an amino acid essential for tumor growth, thereby starving cancer cells. The drug has shown promise in Phase 2 studies and is currently in Phase 3 pivotal trials for indications such as hepatocellular carcinoma and mesothelioma. Polaris is listed on the Taiwan Stock Exchange (ticker: 6550.TW) with a market valuation of approximately $15 billion, reflecting investor confidence in its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 pivotal trial data readout for ADI-PEG 20 in a lead indication65% success
• Q2 2027Regulatory submission (NDA/BLA) in the US or EU55% success
• H1 2027Strategic partnership or licensing deal for ADI-PEG 20 in other territories50% success